Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors
Dittrich, C × Dumez, Herlinde Calvert, H Hanauske, A Faber, M Wanders, J Yule, M Ravic, M Fumoleau, P #
Amer assoc cancer research
Clinical Cancer Research vol:9 issue:14 pages:5195-5204
Purpose: E7070 is a sulfonamide that induces arrest at the G(1)-S boundary with subsequent dose and exposure-dependent apoptosis. The objectives of this study were (a) to determine the maximum-tolerated dose (MTD) and recommended safe dose (RD) of E7070 for additional evaluation, (b) to define the dose limiting toxicity(ies) [DLT(s)], (c) to study the pharmacokinetics of E7070, and (d) to seek preliminary evidence of antitumor activity.